Macquarie completes acquisition of Korea’s biggest hydrogen supplier Deokyang takeover is first investment via Macquarie Korea Opportunities Fund V
Translated by Ryu Ho-joung 공개 2021-12-07 08:07:23
이 기사는 2021년 12월 07일 08:05 thebell 에 표출된 기사입니다.
Macquarie Korea Asset Management has completed its roughly 800 billion won ($676 million) acquisition of Deokyang, the country’s biggest producer and supplier of hydrogen, as the Australia-based investment firm further expands its presence in South Korea’s energy and infrastructure sector.The deal’s closing comes about two months after the hydrogen producer signed with Macquarie to sell itself in October.
Earlier this year Deokyang owner’s family approached several private equity firms about a sale after the company’s founder and honorary chairman Lee Deok-woo died in March and then entered into exclusive discussions with Macquarie.
The acquisition is the first investment via Macquarie’s fifth South Korean infrastructure fund, Macquarie Korea Opportunities Fund V, which invested 200 billion won in the company.
Deokyang is expected to create synergies with Macquarie’s existing portfolio companies in the country’s gas industry. Over the past two years, the investment firm acquired South Korea's biggest industrial gas supplier Daesung Industrial Gases and two regional gas suppliers Haeyang Energy and Seorabeol City Gas.
With more than 60 years in the industry, Deokyang holds approximately a 40% share in the domestic hydrogen market. Based in Ulsan, the company has more than 250 hydrogen tube trailers.
Macquarie plans to accelerate the company’s growth by helping to expand into blue and green hydrogen production through partnerships with energy firms at home and abroad. (Reporting by Seon-young Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- "35년 영업맨, 상장 후 글로벌 시장 노린다"
- [아시아나 화물사업부 M&A]LOC 낸 에어인천·이스타, LOI 낸 에어프레미아
- SK하이닉스의 20조 투자 자신감 '엔비디아 선급금'
- 유가 오르면 정유사 버는 돈 많아질까, 이익구조 뜯어보니
- 캡티브 잡자…퇴직연금 사업자-계열사간 인력 교류
- [스튜어드십코드 모니터]한화운용, '이사 선임·자사주 취득' 주주제안 일부 반대
- [제일약품의 온코닉테라퓨틱스 첫 '신약']제약사 스핀오프 모범선례 '독립성·전문성'에 전권줬다
- [thebell desk]'부동산 PF' 누가 떠안을 것인가
- [VC 경영분석]'펀딩부터 차곡차곡' 리인베스트, BEP 달성 '가시권'
- [thebell interview]"그레이드헬스체인, 인슈어테크 넘어 데이터 회사로"